TY  - GEN
AU  - Berek,J S
AU  - Matulonis,U A
AU  - Peen,U
AU  - Ghatage,P
AU  - Mahner,S
AU  - Redondo,A
AU  - Lesoin,A
AU  - Colombo,N
AU  - Vergote,I
AU  - Rosengarten,O
AU  - Ledermann,J
AU  - Pineda,M
AU  - Ellard,S
AU  - Sehouli,J
AU  - Gonzalez-Martin,A
AU  - Berton-Rigaud,D
AU  - Madry,R
AU  - Reinthaller,A
AU  - Hazard,S
AU  - Guo,W
AU  - Mirza,M R
TI  - Safety and dose modification for patients receiving niraparib
SN  - 1569-8041
PY  - 2019///1223
KW  - Administration, Oral
KW  - Adult
KW  - Body Weight
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Incidence
KW  - Indazoles
KW  - administration & dosage
KW  - Maintenance Chemotherapy
KW  - adverse effects
KW  - Neoplasm Recurrence, Local
KW  - blood
KW  - Ovarian Neoplasms
KW  - Piperidines
KW  - Platelet Count
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Progression-Free Survival
KW  - Retrospective Studies
KW  - Risk Factors
KW  - Thrombocytopenia
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdy181
ER  -